<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663893</url>
  </required_header>
  <id_info>
    <org_study_id>PI 20-2041</org_study_id>
    <nct_id>NCT04663893</nct_id>
  </id_info>
  <brief_title>Peri-Implant and Peri-Prosthetic Fractures: Epidemiology, Morbidity, Mortality, Treatment and Outcome Analysis</brief_title>
  <acronym>PIPPAS</acronym>
  <official_title>Peri-Implant and Peri-Prosthetic Fractures: Epidemiology, Morbility, Mortality, Treatment and Functional Outcome Analysis. A Prospective Multi Center Observational Collaborative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Mutua de Terrassa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Althaia Xarxa Assistencial Universitària de Manresa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Jove, Gijón, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clínico Universitario de Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study supports Spanish data collection and analysis on Periprosthetic and Peri-implant&#xD;
      fractures of the upper and lower limb. Treatment and clinical management of this fractures&#xD;
      are complex and goes along with complications. There will be more than 70 hospitals providing&#xD;
      information. This study will provide evidence on which is the best treatment for every unique&#xD;
      patient. This will help trauma surgeons and geriatricians to provide better treatments, to&#xD;
      improve health care in our society, reducing mortality, morbidity, improving functional&#xD;
      outcomes, and reducing costs, which in turn will be advances in trauma care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no clinical evidence on which are the best treatment options for Periprosthetic and&#xD;
      Peri-implant fractures of the upper and lower limb. This is a multi-center collaborative&#xD;
      study seeking to obtain a big number of patients. Data collection includes previous health&#xD;
      status and quality of life, which is the clinical management and treatment, as well as the&#xD;
      outcome after one month, six months and one year. The investigators will be able to define&#xD;
      risk factors and clinical attitudes, which influence on the patient outcome. And therefore,&#xD;
      be able to establish treatment protocols and give management recommendations based on the&#xD;
      observed clinical evidence to improve healing indexes, morbidity and mortality, function,&#xD;
      grade of autonomy and quality of live.&#xD;
&#xD;
      Main questions to be answered are: 1. which is the epidemiology of Periprosthetic and&#xD;
      Peri-implant fractures and how are they treated in Spain, 2. Identify risk factors for&#xD;
      complications and worse outcomes, 3. which is the morbidity and mortality, 4. influence of&#xD;
      the fracture type and implants already placed on management and outcome, 5. influence of the&#xD;
      treatment on patients' grade of independency, and 6. identified which are the risk factors&#xD;
      for treatment failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Rate of mortality at anytime from fracture diagnose up to 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fracture classification</measure>
    <time_frame>Pre-operatively (Day -1)</time_frame>
    <description>Fracture classification using the UCS for periprosthetic fractures, and the adapted H. Broggi classification for peri-implant fractures. Number of patients in each classification group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment</measure>
    <time_frame>Post-operatively (Day +1)</time_frame>
    <description>Number of patients treated with fixation or revision and fixation or implant removal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fracture healing</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Rate of bone union on X-rays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>EuroQuality of Life 5Dimensions 5Leves (EQ5D5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dependency</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Clinical frailty scale (1-9) 1=very fit, 9=terminally ill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental situation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Pfeiffer test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>FFN-MCD mobility scale (Fragility Fracture Network-Minimum Common Dataset). 1-5: 1=independent mobility, 5=No functional mobility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone protector treatment</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Is the patient under treatment with vitamine D, calcium, bone formation, bone modeling?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life style change</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Need to change place of living because of the fracture or its sequels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical or Surgical complications</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>in need of at least one in-hospital night.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Periprosthetic Fracture of the Upper or Lower Limb</condition>
  <condition>Peri-implant Fracture of the Upper or Lower Limb</condition>
  <condition>Periprosthetic Fractures</condition>
  <condition>Peri-implant Fracture</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients treated for a Periprosthetic or a Peri-implant fracture of the upper or lower&#xD;
        limb by any participant hospital in Spain.&#xD;
&#xD;
        Hospital participation is voluntary and upon request or invitation. 80 hospitals&#xD;
        participating all over Spain&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with the diagnose of Periprosthetic fracture of the shoulder, elbow, hip or&#xD;
             knee. Or patients with the diagnose of Peri-implant fracture of the scapula, humerus,&#xD;
             forearm, pelvis, femur, patella, tibia or fibula. Or patient presenting cut-out or&#xD;
             cut-in after DHS or nail after a proximal humeral fracture.&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Spine PP or PI fracture&#xD;
&#xD;
          -  PP or PI secondary to metastasis or tumoral fracture&#xD;
&#xD;
          -  PP or PI intraoperative fracture&#xD;
&#xD;
          -  PP or PI pathologic fracture&#xD;
&#xD;
          -  PP ankle fracture&#xD;
&#xD;
          -  PP or PI wrist or hand fracture&#xD;
&#xD;
          -  Fixation failure without any new fracture line: except cut-out or cut-in after DHS or&#xD;
             nail of a proximal humeral fracture.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Héctor J Aguado, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico Universitario Valladolid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Castillón, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mútua Universitaria de Terrassa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep M Muñoz Vives, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Althaia Xarxa Assistencial Universitària de Manresa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Ojeda-Thies, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre, Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar Camacho, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Teixidor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Vall d´Hebrón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo García-Portablella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jove, Gijón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adela Pereda-Manso</last_name>
    <phone>+34983420000</phone>
    <phone_ext>86366</phone_ext>
    <email>aperedama@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Montsant Jornet</last_name>
    <email>estudio.pippas@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mutua Universitaria de Tarrasa</name>
      <address>
        <city>Barcelona</city>
        <zip>08080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith López Catena</last_name>
      <email>jlopezcatena@mutuaterrassa.cat</email>
    </contact>
    <investigator>
      <last_name>Pablo Castillón, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith López Catena, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Althaia, Xarxa Assistencial Universitària de Manresa</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M Muñoz Vives, MD PhD</last_name>
      <email>jmmuvi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Josep M Muñoz Vives, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montsant Jornet</last_name>
      <email>mjornet.sc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Camacho, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montsant Jornet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Teixidor, MD</last_name>
      <email>jteixidorserra@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jordi Teixidor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Jove</name>
      <address>
        <city>Gijón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Garcia-Portabella, MD</last_name>
      <email>pgportabella@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pablo Garcia-Portabella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Ojeda-Thies, MD PhD</last_name>
      <email>ojedathies@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina Ojeda-Thies, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Pereda Manso</last_name>
      <phone>+34983420000</phone>
      <phone_ext>86366</phone_ext>
      <email>estudio.pippas@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Héctor J Aguado, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adela Pereda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valladolid</investigator_affiliation>
    <investigator_full_name>Héctor J Aguado</investigator_full_name>
    <investigator_title>MD PhD Associate Professor Trauma/Orthogeriatric unit</investigator_title>
  </responsible_party>
  <keyword>Periprosthetic fracture</keyword>
  <keyword>peri-implant fracture</keyword>
  <keyword>mortality</keyword>
  <keyword>morbidity</keyword>
  <keyword>loosening</keyword>
  <keyword>prosthesis revision</keyword>
  <keyword>fixation</keyword>
  <keyword>osteosynthesis</keyword>
  <keyword>complication</keyword>
  <keyword>ambulate</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Periprosthetic Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>From 1st of January 2022</ipd_time_frame>
    <ipd_access_criteria>Application form to the PIPPAS study office. The applicant must be a study participant and should describe which is the substudy to be held, providing a detailed description and variables need for that reason.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

